ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Bortezomib for Late Antibody-Mediated Rejection After Renal Transplantation: A Single Center Experience of 22 Cases.

J. Choi, J. Jung, S. Chun, S. Shin, Y. Kim, D. Han.

Department of General Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

Meeting: 2017 American Transplant Congress

Abstract number: B79

Keywords: Antibodies, B cells, Rejection, Renal function

Session Information

Session Name: Poster Session B: Antibody Mediated Rejection in Kidney Transplant Recipients II

Session Type: Poster Session

Date: Sunday, April 30, 2017

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Despite of tradifional treatments for AMR, such as plasapheresis, ingravenous immunoglobulin, and rituximab, current treatment for antibody-mediated rejection(AMR) after renal transplantation is insufficient. Recently, Bortezomib has been used for refractory late AMR. Thus, we reviewed our cases that treat late AMR with bortezomib and investigate the effect of bortezomib in renal transplantation. We treated 22 cases with bortezomib for late AMR. One case is diagnosed late AMR based on serologic test and the others were based on renal biopsy. Bortezomoib(1.3mg/m2) was administered on days 1,4,8,and 11. Clinical characteristics, biopsy findings assessed by 2013 Banff criteria, donor specific antibodies(DSA), renal function, and graft survival were analyzed. AMR and acute cellular rejection were accompanied in 21cases and C4d+ were identified in 10 cases. MI score (g+ptc) was 4.23±1.31. Number of previous rejection treatment history was 2.0±1.8. There were significant improvement in the mean eGFR (21.09±10.88 vs. 24.10±12.99 at 2 weeks, p=0.014; 21.09±10.88 vs. 33.15±11.66 at 6 months, p=0.046) and sCr (3.93±2.55 vs. 3.51±2.41 at 2 weeks, p=0.023; 3.93±2.55 vs. 2.40±1.20 at 6 months, p=0.046) at 2 weeks and 6 months after treatment comparing those at the time of AMR diagnosis. MFI of DSA were significantly decreased after treatment ( Class I , 7254.0±4025.2 vs. 4732.8±3188.0, p=0.056 ; Class II 11225.2±5847.0 vs. 8953.7±5008.6, p=0.005). However, 13(59.1%) cases performed renal biopsy again within 220.8±143.8(1-511)days. Graft failure were developed in 8 cases(36.4%) and it took 12.7±7.2months (1-23) after treatment. Bortezomib can be effective on decreasing the MFI of DSA as anti-humoral treatment in late AMR. And it showed improvement of renal function in early periods. However, it is uncertain whether it can be useful for maintain graft function of not. Large scales and long-term follow-up study is needed.

CITATION INFORMATION: Choi J, Jung J, Chun S, Shin S, Kim Y, Han D. Bortezomib for Late Antibody-Mediated Rejection After Renal Transplantation: A Single Center Experience of 22 Cases. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Choi J, Jung J, Chun S, Shin S, Kim Y, Han D. Bortezomib for Late Antibody-Mediated Rejection After Renal Transplantation: A Single Center Experience of 22 Cases. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/bortezomib-for-late-antibody-mediated-rejection-after-renal-transplantation-a-single-center-experience-of-22-cases/. Accessed May 27, 2025.

« Back to 2017 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences